Quick Answer
Coherus Oncology, Inc. reported Operating Income of -$181.13 million for fiscal year 2025.
Coherus Oncology, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$181.13M | +9.3% |
| 2024 | -$199.65M | +1.7% |
| 2023 | -$203.20M | +20.9% |
| 2022 | -$256.88M | +2.6% |
| 2021 | -$263.86M | -268.8% |
| 2020 | $156.32M | +45.1% |
| 2019 | $107.77M | +152.7% |
| 2018 | -$204.42M | +11.9% |
| 2017 | -$232.14M | -100.2% |
| 2016 | -$115.93M | +47.1% |
| 2015 | -$219.07M | -238.7% |
| 2014 | -$64.68M | -79.7% |
| 2013 | -$35.99M | +6.6% |
| 2012 | -$38.52M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$44.33M | +5.4% | +2.5% |
| June 30, 2025 | -$45.49M | -14.8% | -0.1% |
| March 31, 2025 | -$45.44M | +33.0% | +3.0% |
| September 30, 2024 | -$46.86M | -46.4% | -18.2% |
| June 30, 2024 | -$39.63M | -14.7% | +41.5% |
| March 31, 2024 | -$67.79M | -0.1% | -111.8% |
| September 30, 2023 | -$32.01M | +60.2% | +7.3% |
| June 30, 2023 | -$34.54M | +21.5% | +49.0% |
- Coherus Oncology, Inc. showed an increase of +9.3% in Operating Income compared to the prior fiscal year.
- Over the 2012–2025 period, Coherus Oncology, Inc.’s operating income has declined by 370.3% (from -$38.52 million to -$181.13 million).
- The most recent figure is from Coherus Oncology, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: